Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. [electronic resource]
Producer: 20160115Description: 534-43 p. digitalISSN:- 1879-114X
- Budgets
- Cost-Benefit Analysis
- Dasatinib -- economics
- Drug Costs
- Humans
- Imatinib Mesylate -- economics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Leukemia, Myeloid, Chronic-Phase -- drug therapy
- Markov Chains
- Protein Kinase Inhibitors -- economics
- Pyrimidines -- economics
- Quality of Life
- Quality-Adjusted Life Years
- Thailand
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.